Biogen (BIIB) PT Raised to $320 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
RBC Capital on Biogen (BIIB): 'FDA Summary Review Now Available; We Believe Suggests High Amenability For Future Full Leca Approval'
January 10, 2023 9:50 AM ESTRBC Capital analyst Brian Abrahams reiterated an Outperform rating and $362.00 price target on Biogen (NASDAQ: BIIB).
The analyst comments "FDA's Summary Review of Leqembi (lecanemab) is now available, and we analyzed it in depth. Overall, given that the benefit/risk assessment appeared... More
